Trump Executive Order Seeks to Accelerate Psychedelic Drug Development for PTSD, Addiction

An executive order signed by President Donald J. Trump on April 18, 2026, directs federal agencies to accelerate the development and potential approval of psychedelic-based therapies for conditions such as posttraumatic stress disorder (PTSD), depression, and substance use disorders. This marks a notable shift in federal drug policy, emphasizing expanded research and faster regulatory pathways alongside maintenance of existing legal restrictions on currently unapproved substances.^1,2

The order does not legalize psychedelic drugs but instead focuses on streamlining clinical development, enhancing federal coordination, and improving access pathways for investigational therapies. For pharmacists, the policy introduces emerging considerations around future therapeutic classes, regulatory changes, and patient safety in a rapidly evolving area of mental health care.^1,2

Executive Order Mandates Faster FDA Review, Expanded Access Pathways

Central to the executive order is a directive for the FDA to expedite the review of psychedelic therapies, particularly those designated as “breakthrough therapies.” This includes the use of priority review mechanisms, such as the granting of a Commissioner’s National Priority Voucher, that could shorten regulatory timelines from the traditional 6 to 10 months to as little as 1 to 2 months in certain cases.^1,2

The order also calls for the following:

• Development of new FDA guidance to facilitate clinical trials of psychedelic agents
• Use of federal programs, such as the Right to Try pathway, to allow access for eligible patients with serious or life-threatening conditions
• Improved data sharing between federal agencies, including the FDA and the US Department of Veterans Affairs
• Consideration of expedited rescheduling if products receive FDA approval^1,2

Additionally, the federal government will allocate approximately $50 million to support research into ibogaine and other psychedelic compounds, with a particular focus on veteran populations.^1,2

Despite these measures, psychedelic substances—including ibogaine, psilocybin, and lysergic acid diethylamide—remain classified as Schedule I drugs under the Controlled Substances Act, indicating no currently accepted medical use and a high potential for abuse. However, the executive order calls for the attorney general to review any product containing a Schedule I substance that has completed a phase 3 trial for a serious mental health disorder “so that rescheduling, if appropriate, may proceed as quickly as practicable.”²

Focus on PTSD, Addiction, and Treatment-Resistant Conditions

The executive order emphasizes conditions with significant unmet medical need, including PTSD, major depressive disorder, and opioid use disorder. The policy is partly driven by ongoing concerns around veteran mental health and suicide rates, as well as limitations of existing pharmacologic and behavioral therapies. Recent data highlight the disparity; the rate of suicide among veterans in 2022 was 34.7 per 100,000, compared with 17.1 per 100,000 for nonveterans, according to RAND.^1,3

Ibogaine, a psychoactive compound derived from a West African shrub, is a central focus of the initiative. Although not approved in the US, it has been used internationally for addiction treatment and has shown early signals of efficacy in reducing withdrawal symptoms and cravings. However, evidence remains limited to small studies, and safety concerns—particularly cardiac arrhythmias—have been documented.^4,5

Other psychedelic agents, including psilocybin, received FDA breakthrough therapy designation for treatment-resistant depression, reflecting growing interest in their therapeutic potential when used in controlled clinical settings with psychological support.⁶

Pharmacist Considerations: Emerging Therapies, Safety, and Regulation

Although psychedelic therapies remain investigational, the executive order has several implications for pharmacists, particularly those involved in mental health, specialty pharmacy, and clinical research. Pharmacists should be aware that no psychedelic therapies are currently approved by the FDA, and these agents remain federally restricted. Any future clinical use will depend on successful trial outcomes, regulatory approval, and potential rescheduling.

Safety considerations in this sector of medicine are substantial. Psychedelic compounds may carry risks, including cardiovascular effects, psychiatric destabilization, and drug-drug interactions. Pharmacists will play a key role in evaluating these risks, particularly in patients with comorbid conditions or those receiving complex medication regimens. In specific settings, such as oncology care, this becomes especially critical, given the litany of medications patients with cancer are prescribed.⁷

Pharmacists may become increasingly involved in clinical trials and expanded access programs. The executive order’s emphasis on accelerating research and enabling access through pathways such as Right to Try may increase opportunities for pharmacist participation in investigational drug management and patient counseling. Overall, pharmacists can continue to advocate for the legality of medicines with proven clinical trial backgrounds, especially for vulnerable populations.⁷

Balancing Innovation With Evidence

The executive order reflects growing bipartisan and public interest in psychedelic therapies, but experts continue to emphasize the need for rigorous clinical evidence before widespread adoption. Current data for many agents remain limited, and long-term safety and efficacy have not been fully established. Importantly, the policy does not bypass FDA standards for approval. Instead, it aims to reduce administrative barriers and prioritize review timelines for therapies addressing serious mental health conditions.

For pharmacists, this distinction is critical. Although the policy may accelerate development, it does not change the fundamental requirement for evidence-based evaluation of safety, efficacy, and quality. However, if successful, the initiative could lead to the introduction of novel treatment options for patients with treatment-resistant mental health disorders, potentially reshaping pharmacologic approaches to PTSD, depression, and addiction.

In anticipation, pharmacists should monitor developments in psychedelic research, regulatory changes, and clinical guidelines. As these therapies progress through the pipeline, pharmacists will be essential in ensuring safe implementation, patient education, and integration into multidisciplinary care models.

REFERENCES

1. Fact sheet: President Donald J Trump is accelerating medical treatments for serious mental illness. The White House. April 18, 2026. Accessed April 20, 2026. https://www.whitehouse.gov/fact-sheets/2026/04/fact-sheet-president-donald-j-trump-is-accelerating-medical-treatments-for-serious-mental-illness/

2. Accelerating medical treatments for serious mental illness: executive orders. The White House. April 18, 2026. Accessed April 20, 2026. https://www.whitehouse.gov/presidential-actions/2026/04/accelerating-medical-treatments-for-serious-mental-illness/

3. Ramchand R, Montoya T. Suicide among veterans. RAND. May 22, 2025. Accessed April 20, 2026. https://www.rand.org/pubs/perspectives/PEA1363-1-v2.html

4. Williams S. Psychoactive drug ibogaine effectively treats traumatic brain injury in special ops military vets. Stanford Medicine. January 5, 2024. Accessed April 20, 2026. https://med.stanford.edu/news/all-news/2024/01/ibogaine-ptsd.html

5. Brunt TM. Rare but relevant: ibogaine and cardiovascular complications—prolonged QT interval and ventricular arrhythmias. Addiction. Published online January 20, 2026. Accessed April 20, 2026. doi:10.1111/add.70319

6. Heal DJ, Smith SL, Belouin SJ, Henningfield JE. Psychedelics: threshold of a therapeutic revolution. Neuropharmacology. 2023;236:109610. doi:10.1016/j.neuropharm.2023.109610

7. Whitman A. Investigating the pharmacist’s role in psychedelic-assisted psychotherapy for patients with cancer. Pharmacy Practice in Focus: Oncology. Published online June 27, 2025. Accessed April 20, 2026. https://www.pharmacytimes.com/view/investigating-the-pharmacist-s-role-in-psychedelic-assisted-psychotherapy-for-patients-with-cancer